Macrophage migration inhibitory factor (MIF) is pleiotropic cytokine that has multiple effects in many inflammatory and immune diseases. This study reveals a potential role of MIF in acute kidney injury (AKI) in patients and in kidney ischemic reperfusion injury (IRI) mouse model in MIF wild-type (WT) and MIF knockout (KO) mice. Clinically, plasma and urinary MIF levels were largely elevated at the onset of AKI, declined to normal levels when AKI was resolved and correlated tightly with serum creatinine independent of disease causes. Experimentally, MIF levels in plasma and urine were rapidly elevated after IRI-AKI and associated with the elevation of serum creatinine and the severity of tubular necrosis, which were suppressed in MIF KO mice. It was possible that MIF may mediate AKI via CD74/TLR4-NF-κB signalling as mice lacking MIF were protected from AKI by largely suppressing CD74/TLR-4-NF-κB associated renal inflammation, including the expression of MCP-1, TNF-α, IL-1β, IL-6, iNOS, CXCL15(IL-8 in human) and infiltration of macrophages, neutrophil, and T cells. In conclusion, our study suggests that MIF may be pathogenic in AKI and levels of plasma and urinary MIF may correlate with the progression and regression of AKI.
| INTRODUC TI ON
Macrophage migration inhibitory factor (MIF) is a pleiotropic protein and has multiple roles in both innate and adaptive immunity. 1, 2 Many studies have shown that MIF is protective in many inflammatory and immune diseases including sepsis, rheumatoid arthritis and systemic lupus erythematosus. [3] [4] [5] MIF also participates in many inflammatory kidney diseases, 6 including rapidly progressive glomerulonephritis, 7 lupus nephritis, 8 anti-glomerular basement membranous (GBM) glomerulonephritis, 9 anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, 10 renal allograft rejection 11, 12 and acute kidney injury (AKI). 13 Clinically, plasma MIF levels are significantly elevated in patients with septic shock and MIF is a potential biomarker for renal replacement therapy for AKI after liver transplantation. 14, 15 In addition, increased renal MIF levels are also reported in a mouse model of IRI-AKI. 16 All these observations suggest that MIF may be important in AKI. However, the role and mechanisms of MIF in AKI remains to be further investigated.
In the present study, we first demonstrate that both serum and urinary levels of MIF are highly elevated in AKI patients and associated with the onset, the severity and the recovery of AKI. We also uncover the pathogenic role of MIF in AKI induced in MIF knockout (KO) mice by using an IRI-AKI mouse model, a common cause of AKI.
Furthermore, the potential role and mechanisms of MIF in the pathogenesis of AKI are investigated.
| ME THODS

| Patients with AKI
According to RIFLE criteria ( Figure S1A ), a total of 47 patients with AKI and 30 healthy controls without evidence for any abnormalities or diseases from the Physical Examination Center were included in this study. AKI patients with diabetes, chronic kidney disease (CKD) and multiorgan dysfunction syndrome (MODS) were excluded from the study. Of 47 AKI patients, 10 patients were sequentially measured for both plasma and urinary MIF levels over a period of 14 days from initial onset of AKI to the recovery phase, while other 37 patients received plasma and urinary MIF analysis at the onset of AKI.
The onset of AKI was defined at the first day of AKI, while the recovery stage of AKI was defined when serum creatinine returned to the baseline level. Serum creatinine and urine output were measured every 2 days. All patients gave written and informed consent, and the study protocol was approved by the Institutional Review Board of Sun Yat-sen Memorial Hospital.
Plasma and urinary levels of MIF were measured by using the Quantikine ® human MIF ELISA kit (R&D Systems), whereas serum creatinine was analysed using an automatic biochemical analyzer (Hitachi 7600, Tokyo, Japan).
| Ischemic AKI mouse model
Male MIF KO mice and littermate WT mice (C57/BL6 background) at 8-12 weeks of age (20-25 g body weight) were used as described previously. 17 To induce AKI, bilateral kidney artery clamping was applied for 45 min as described in our previous study. 18 Mice were sacrificed at day 1 to day 3 after AKI operation. The operation protocols were approved by Animal Experimental Committee of The Chinese University of Hong Kong.
| Renal function and histology
Serum was collected for renal creatinine detection from day 1 to day 3 after AKI. Serum creatinine was detected by using a direct
Creatinine LiquiColor kit (Stanbio Laboratory, Boerne, TX, USA).
Renal pathology is examined by periodate-Schiff (PAS) staining (Sigma-Aldrich, 395B, St. Louis, MO, USA), formalin-fixed kidney tissues were embedded into paraffin and sectioned (3 μm), and then followed by PAS staining. The number of tubular necrosis was scored at ×40 magnification and a total of 10 fields of cortical versions were examined and calculated as previously study described.
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| Immunohistochemistry
Immunohistochemistry was performed on paraffin embedded slides for renal MIF, CD74 expression, pro-inflammatory cytokines as MCP-1 and TNF-α expression, and for infiltration of neutrophils, F4/80 + macrophages and CD3 + T cells as described previously. 9, 11, [22] [23] [24] The catalogue number of the antibodies for immunohistochemistry 
| Western blot analysis
Western blotting was performed as described previously. were determined by normalizing to the housekeeping gene GAPDH.
The primers of this cytokines were shown in Table S1 .
| Statistical analysis
Experimental and clinical data were statistically analysed using SPSS 19.0. GraphPad Prism (Prism 5.0; GraphPad software, La Jolla, CA, USA) was used to generate figures. All metric data were tested for normal distribution using the Shapiro-Wilk W test. For clinical data, normally distributed data were compared using the Student's t test. Non-normally distributed data were compared using the Mann-Whitney U test.
Non-parametric data were compared using the Fisher's exact test. For correlation analysis, a linear regression analysis was performed using the Pearson correlation coefficient. For animal experimental data, results
were presented as means ± SEM. The differences between groups were analysed by Student's t test. In all cases, P < 0.05 was considered statistically significant, and two-sided testing was used.
| RE SULTS
| Serum and urinary MIF levels are significantly higher in patients with AKI and correlate with the progression or regression of AKI
The baseline characteristics, comorbidities, causes of patients and healthy controls in this study were described in Tables 1 and
Deficiency of MIF protects against IRI-AKI in mice. A, Serum creatinine levels in MIF wild-type mice (MIF WT) and knockout (MIF KO) mice with IRI-AKI were measured by ELISA. B, PAS staining and quantitative analysis of tubular necrosis in IRI-AKI from MIF WT and MIF KO mice. Note that mice lacking MIF are protected from AKI indicated by decreasing serum levels of creatinine and tubular necrosis (*). Results are presented as mean ± SEM (n = 6, per group). *P < 0.05, **P < 0.01 and **P < 0.001 compared with the sham-treated group; # P < 0.05, ## P < 0.01 and ### P < 0.001 compared to MIF WT mice at the same time-point. Scale bar: 50 μm F I G U R E 2 Plasma and renal MIF levels are significantly elevated in mice with IRI-AKI. A, Plasma MIF levels in IRI-induced AKI from day 1 to day 3. B, Linear correlation between plasma or urinary MIF levels and serum creatinine at day 1. C, Linear correlation between plasma levels of MIF and the degree of tubular necrosis at day 1. D, mRNA level of MIF in IRI-induced AKI from day 1 to day 3. E, Immunohistochemistry reveals that renal MIF is predominantly produced by renal tubular epithelial cells in injured kidneys of mice with IRI-AKI. Data are presented as the mean ± SEM. Each dot represents one AKI mouse. **P < 0.01 and ***P < 0.001 compared with the sham group (n = 6, per group). Scale bar: 100 μm Plasma MIF levels were elevated in AKI patients compared to healthy controls (Table 2, Figure 1A ). As shown in Table 2 and Figure 1B , elevated urinary MIF was also detected in these AKI patients. In addition, correlation analysis demonstrated that increased plasma and urinary MIF was closely correlated with elevated serum creatinine levels in patients with AKI ( Figure 1C-E) . Interestingly, plasma MIF and urinary MIF levels largely declined in patients when AKI was resolved ( Figure 1F-H) . These findings indicated that plasma MIF and urinary MIF levels were closely correlated with the progression or regression of AKI clinically.
| MIF expression in a mouse model of ischemic AKI
We further investigated whether there is a correlation between plasma MIF and IRI-AKI in mice. In IRI-AKI mice, the levels of plasma MIF rapidly increased as early as 6 hours, preceding the development of acute tubular necrosis and elevated serum creatinine at 24 hours after AKI ( Figure S3 ). Plasma MIF remained high at 24 hours after AKI and was associated with a severe renal injury including elevated serum creatinine and severe acute tubular necrosis ( Immunohistochemistry demonstrated that the renal tubular epithelial cells (TECs) was the dominant source of MIF production, particularly damaged TECs in the kidney in IRI-AKI ( Figure 2F ).
| MIF promotes IRI-AKI in mice
We next examined whether MIF play a pathogenic role in IRI-AKI in MIF WT/KO mice. As shown in Figure 3A , MIF WT mice showed a rapid increase in plasma MIF levels at the onset of AKI on day one with elevated serum creatinine, which was obviously reduced in after MIF deletion ( Figure 3A) . Strikingly, serum levels of creatinine decreased to nearly normal level in the MIF-KO mice 72 hours after IRI-AKI but not in WT mice. These findings suggest that a rapid increase in serum MIF contributes to the onset and severity of AKI and delays the recovery time after AKI. PAS staining revealed that deletion of MIF obviously reduced tubular necrosis in IRI-AKI mice ( Figure 3B and C).
| MIF mediates IRI-AKI by enhancing inflammation in the kidney
Renal inflammation plays an important role in the process of AKI.
We examined the mRNAs levels of encoding pro-inflammatory cytokines and chemokines as MCP-1, TNF-α, IL-6, IL-1β, CXCL15
(also known as IL-8 in human) and iNOS were greatly up-regulated in the kidney of IRI-AKI in MIF WT mice, which were markedly sup- 
| Expression of renal MIF is associated with upregulation of CD74 and TLR4 receptors in the kidney with AKI
We then investigated the possible molecular mechanisms as to how MIF promotes AKI in mice. Immunohistochemistry showed that CD74, a MIF-specific receptor, was highly expressed by both tubular epithelial cells and inflammatory cells infiltrating to the kidney of IRI-AKI in mice, demonstrating that MIF-CD74 signalling is highly active in the AKI kidney after IRI. All these changes were largely blocked after MIF deletion ( Figure 6A ). Similar results were also found by Western blot analyses demonstrating that a marked upregulation of renal CD74 in MIF WT mice was inhibited after MIF deletion ( Figure 6B ). NF-κB signalling was tightly associated with MIF-mediated inflammation and renal injury in IRI-AKI. In contrast, deletion of MIF inactivated NF-κB signalling by largely reducing the phosphorylation levels of NF-κB/p65 and IKBα ( Figure 6C and D).
All these findings suggest that MIF may possibly act through CD74
to activate NF-κB-dependent renal inflammation in AKI.
It has been reported that MIF is capable of inducing TLR4 to an induce inflammatory response in vitro, 25 suggesting an alternative pathway of MIF/TLR4 interaction during the process of inflammation. As shown in Figure 6E , western blot analysis detected that TLR4 was markedly up-regulated in the kidney after AKI, whereas, deletion of MIF down-regulated TLR4 expression in the kidney.
| D ISSCUSS I ON
Macrophage migration inhibitory factor was a stress molecular that release quickly under disease conditions including surgery, sepsis, acute massive gastrointestinal bleeding or kidney diseases. It is reported that MIF is rapidly released and peaks within one hour during operation. 26 Here, we reported that plasma MIF was closely correlated with the progression and regression in patients with AKI.
Indeed, both circulating and urinary MIF was abundantly released at the initial onset of AKI and decreased to baseline levels when AKI recovered, which was independent of the causes of AKI. The elevated plasma and urinary MIF were also closely correlated with the serum levels of creatinine. This was consistent with previous studies in AKI patients with sepsis and liver transplantation in which high levels of plasma MIF are closely associated with poor clinical outcome, 14, 27 whereas removal of circulating MIF by CRRT (renal replacement therapy) largely improved the AKI survival. 28 Similarly, a close correlation between plasma MIF and serum creatinine was also found in the present study. Indeed, plasma MIF was rapidly released with the peak at 6 hours after AKI, preceding the elevated serum levels of creatinine and severe tubular necrosis at 24 hours after AKI, suggesting a causal effect of MIF in AKI. It is known that tubular epithelial cells are one of the major cell types for MIF production in the consequence of kidney injury. 24, 29 In our study, we also found that MIF was highly expressed in injured cortical tubules as well as the MIF released to circulation by damaged tubular cells in response to IRI, this cause a marked increase of MIF levels in both plasma and urine. Similar results were reported in a mouse model of UUO. 16 When AKI was resolved, renal MIF expression was reduced and MIF levels in plasma and urine declined to baseline again. These observations are consistent with the previous studies that levels of MIF reflect the severity of kidney injury in acute pyelonephritis, 13 human renal allograft rejection, 30 glomerulonephritis. 31 The most significant thing is that we revealed MIF plays a pathogenic role in IRI-AKI. This was supported by the finding that mice lacking MIF were protected against IRI-induced AKI by significantly lowering serum creatinine and inhibiting TEC necrosis after IRI. This finding was consistent with our previous study in cisplatin-induced AKI. 32 Interestingly, inhibition of AKI by blocking MIF with a MIF inhibitor RPS19 reveals that targeting MIF may be a novel therapeutic potential for AKI. 32 The pathogenic role of MIF has been reported in many inflammatory kidney diseases including rapidly progressive glomerulonephritis, 7 lupus nephritis, 8 anti-glomerular basement membranous (GBM) glomerulonephritis, 9 ANCA-associated vasculitis, 10 renal allograft rejection 11, 12 and AKI. 13 The present study
showed that the development of AKI is associated with a rapid and Stoppe's study, female mice were used, in contrast, we used male mice in the present study. This may also explain the discrepancy between our study and Stoppe's study. Interestingly, the same group also reported that high level of MIF-2 predicts organ dysfunction after myocardial ischemia/reperfusion injury. 43 Nevertheless, the pathogenic role of MIF in AKI is warrant for further investigation.
It was possible that MIF may mediate AKI via CD74/TLR4-NF-κB signalling. It is well known that MIF acts via CD74 to exert its biological activities in many kidney diseases, 44 and that deletion of CD74
can protect against NTS-induced acute kidney disease. 45 Thus, in the present study, genetic deletion of MIF led to the down-regulation of CD74 and TLR4 and consequently to the inactivation of downstream NF-κB signalling and the inhibition of NF-κB-dependent renal inflammation. Activated macrophages produce high levels of MIF, 46 as well, this released MIF further enhances inflammation via recruiting and activating more macrophages. This may well explain macrophage-mediated renal inflammation as a key process in the pathogenesis of AKI. 9 MIF deficiency protected against IRI-AKI by inhibiting CD74/TLR4-NF-κB-dependent up-regulation of MCP-1, TNF-α, IL-1β, IL-6, CXCL15 (IL-8) and iNOS and by blocking the infiltration of neutrophils, macrophages and T cells to the injured kidney.
In conclusion, our study suggests that MIF may be pathogenic in AKI and levels of plasma and urinary MIF may correlate with the progression and regression of AKI. Targeting MIF may therefore serve a potential method for the therapy of IRI-AKI. 
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